ArticleVirology journal2013
Characterising the biology of novel lytic bacteriophages infecting multidrug resistant Klebsiella pneumoniae.
Article in Virology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 157 citations in OpenAlex.
- Antimicrobial Potential and Genomic Insights of Novel Klebsiella Phage SBP against K-112 Serotype.Current microbiology · 2026Article
- Isolation and Characterization of aAntibiotics (Basel, Switzerland) · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients.BMC microbiology · 2026Article
- Complete genome sequence of Mulvp2, anMicrobiology resource announcements · 2026Article
- Characterization of broad host range bacteriophages vKpIN31 and vKpIN32 against hospital-acquired Klebsiella pneumoniae in Dakar, Senegal.Scientific reports · 2025Article
- Combined experimental and in silico elucidation of KP27 endolysin reveals a phage derived antibacterial with pH and thermal robustness.Scientific reports · 2025Article
- Characterization and genomic insights into bacteriophages Kpph1 and Kpph9 against hypervirulent carbapenem-resistantVirulence · 2025Article
- Newly isolated bacteriophages show efficacy and phage-antibiotic synergy in vitro against the equine genital pathogens Klebsiella pneumoniae and Pseudomonas aeruginosa.BMC veterinary research · 2025Article
- Phage Host Range Expansion Through Directed Evolution on Highly Phage-Resistant Strains ofInternational journal of molecular sciences · 2025Article
- Dual Nature of Bacteriophages: Friends or Foes in Minimally Processed Food Products-A Comprehensive Review.Viruses · 2025Review
- Klebsiella Lytic Phages InduceViruses · 2025Article
- Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: The current status and future prospects.Infectious medicine · 2025Review
- A VersaTile Approach to Reprogram the Specificity of the R2-Type Tailocin Towards Different Serotypes ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Bacteriophage therapy: a possible alternative therapy against antibiotic-resistant strains ofFrontiers in microbiology · 2025Review
- Characterizing the bacteriophage PKp-V1 as a potential treatment for ESBL-producing hypervirulent K1Veterinary world · 2024Article
- The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.Virology journal · 2024Review
- Genome sequence of theMicrobiology resource announcements · 2024Article
- Isolation and characterization of two novel bacteriophages against carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembers of the genus Klebsiella are among the leading microbial pathogens associated with nosocomial infection. The increased incidence of antimicrobial resistance in these species has propelled the need for alternate/combination therapeutic regimens to aid clinical treatment. Bacteriophage therapy forms one of these alternate strategies.
methodsElectron microscopy, burst size, host range, sensitivity of phage particles to temperature, chloroform, pH, and restriction digestion of phage DNA were used to characterize Klebsiella phages. RESULTS AND
conclusionsOf the 32 isolated phages eight belonged to the family Myoviridae, eight to the Siphoviridae whilst the remaining 16 belonged to the Podoviridae. The host range of these phages was characterised against 254 clinical Enterobacteriaceae strains including multidrug resistant Klebsiella isolates producing extended-spectrum beta-lactamases (ESBLs). Based on their lytic potential, six of the phages were further characterised for burst size, physicochemical properties and sensitivity to restriction endonuclease digestion. In addition, five were fully sequenced. Multiple phage-encoded host resistance mechanisms were identified. The Siphoviridae phage genomes (KP16 and KP36) contained low numbers of host restriction sites similar to the strategy found in T7-like phages (KP32). In addition, phage KP36 encoded its own DNA adenine methyltransferase. The φKMV-like KP34 phage was sensitive to all endonucleases used in this study. Dam methylation of KP34 DNA was detected although this was in the absence of an identifiable phage encoded methyltransferase. The Myoviridae phages KP15 and KP27 both carried Dam and Dcm methyltransferase genes and other anti-restriction mechanisms elucidated in previous studies. No other anti-restriction mechanisms were found, e.g. atypical nucleotides (hmC or glucosyl hmC), although Myoviridae phage KP27 encodes an unknown anti-restriction mechanism that needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.